
1 2 IN THE COURT OF COMMON PLEAS OF PHILADELPHIA 3 COUNTY, PENNSYLVANIA 4 5 6 7 **GRO-A** a minor, by 8 and through his parents and 9 natural guardians, GRO-A 10 and **GRO-A** husband and ١, 11 wife, and in their own right 12 Plaintiffs 13 vs NOVEMBER TERM, 1990 14 ARMOUR PHARMACEUTICAL 15 COMPANY NO. GRO-C 16 17 18 ORAL DEPOSITION OF CHRISTOPHER ROY BISHOP 19 Held at: Richards Butler, Solicitors, Beaufort House 20 15 St Botolph Street, London EC3&A 7EE, England 21 on June 6th, 1990 22 23 VOLUME 1 24 25 Transcribed from the Stenotyped Notes of Chilton Vint & Co. 26 Verbatim Reporters, 24 Chancery Lane, London W.C.2A 1LS 27 Telephone: (01144)(71) 405.9147 28 EXHIBIT 1


CGRA0000521 0001

1 2 3 4 GRO-A and GRO-A 5 GRO-A, his wife, 6 Plaintiffs 7 8 vs NOVEMBER TERM, 1990 ARMOUR PHARMACEUTICAL 9 COMPANY and 10 RORER GROUP, INC. 11 NO. GRO-C 12 GRO-A a minro, by 13 and through his parents and 14 natural guardians, GRO-A 15 GRO-A and GRO-A 16 GRO-A , husband and wife, 17 and in their own right 18 Plaintiffs 19 20 vs NOVEMBER TERM, 1990 ARMOUR PHARMACEUTICAL 21 COMPANY and 22 RORER GROUP, INC. and 23 RHONE-POULENC RORER, INC. 24 NO. GRO-C 25 26 27 28 2


÷.

CGRA0000521_0002





CGRA0000521_0004



I, Ruth Bronzite, Accredited Court Reporter, hereby certify that I took stenotype notes in the deposition of Christopher Roy Bishop and the foregoing pages 1-244 are a true and accurate transcript of my said stenotype notes to the best of my skill and ability. **GRO-C** [Ruth Bronzite]

MR CHRISTOPHER ROY BISHOP, sworn Examination by MR SHRAGER

MR SHRAGER: I suppose the only thing I need to say on record preliminarily is that these depositions are being taken, as I understand it, pursuant to agreement between Counsel and pursuant to the Pennsylvania Rules of Civil Procedure and, as in the previous depositions, I assume under all captions. I do not recall offhand what the stipulation was, but whatever stipulation we had previously is fine, or any other you prefer.

11 MR FUSON: No, that is fine.

1

2

3

4

5

6

7

8

9

10

25

26

27

28

I notice that Mr Christie is here and he is MR SHRAGER: 12 scheduled to be deposed upon the completion of Mr 13 Bishop's deposition. I believe, as a witness, unless 14 he is represented to be a managing agent, he ought to 15 be excused for his benefit. 16 That is not intended as any disrespect to him but, as we would understand as 17 attorneys, in order to sequester the witnesses. 18 Will you request him to be excused, Mr Fuson? 19

20 MR FUSON: I think it is appropriate for him to attend the deposition, having been designated to do so on behalf of the company.

23 MR SHRAGER: We cannot get that matter resolved here today,
24 so I really see no option other than to proceed.

Acting through Richards Butler, and with Mr Fuson's cooperation, Armour U.K. - if I may use that reference - has been good enough to make available documents. The way I intend to proceed, which I expect

1		Short pause for reading) Okay?
2	Α.	Okay.
3	Q.	Read it? Let me direct your attention to the first
4		page. Case No. 1, Dr Van den Berg's patient. That is
5		a case you referred to in the July document. Correct?
6	А.	Correct.
7	Q.	Case No. 2, the Gil White patient is again a case you
8		referred to in the July document. Is that correct?
9	Α.	Correct.
10	Q.	And the points you are making underneath case 1 and
11		case 2, you are making - may I fairly assume in the
12		context of a marketing person - as issues that could be
13		raised to dispute causation in those instances with HT
14		Factorate. Is that right?
15	Α.	Correct.
16	Q.	Let us go to the second page. Case 3 is called
17		"Unpublished and classified personal communications
18		Lewisham." That is in fact, is it not, a second case
19	2	of Dr Whitmore's?
20	А.	I do not know what case it is of Dr Whitmore's.
21	Q.	Right. Just hold that document in place, and let me
22		show you a document dated February 28, 1986 from Mr
23	-	Christie to Dr Harris referring to Patient 2, with the
24		reference - parenthetically - "(Reported to me by Dr
25		Whitmore by telephone on 26/2/86)". Look at the
26		content of Mr Christie's reference and tell me whether
27		you are now persuaded that case No. 3 is the Lewisham
28		reference being a second patient of Dr Whitmore's?
	1	

(Memo handed to the witness. Pause for reading) 1 That is the only reference I am going to make, I assure you 2 to the February 28, 1986 document this time. My sole 3 question is whether you are satisfied Case 3 carried on 4 page 2 of the June 19, 1986 Bishop to Lucas document is 5 Dr Whitmore's second case? 6 It would appear to be so. 7 A. 8 2. Return to the second page of the June 19 document and I ask you whether it is correct, if before we go 9 further with that page, that neither of Dr Whitmore's 10 reports appear in your July document, your July 4, 1986 11 document? I represent to you there is no reference to 12 it at all? 13 14 MR FUSON: I think the July document probably speaks for itself. 15 MR SHRAGER: I agree with you, and that is why I took the 16 liberty of saying it. 17 18 MR FUSON: Then we can move on to the next question. 19 MR SHRAGER: All right. My next question: do you agree with that, Sir? 20 MR FUSON: You are not moving on to the next question. 21 22 MR SHRAGER: If I am incorrect at some point, be good enough to correct me, but on page 2 - I am now taking you back 23 to the July 24 25 A. May I look at that? 26 2. Yes, of course you may. In the July 4 document on the second page, you make reference to "In-Vitro" studies 27 and By "In-Vitro" you intended to refer to what? 28

1 A. In the laboratory.

2	Q. Yes. You say that "Many investigators, including J.S.
3	McDougal et.al." - referring to an August 1985
4	reference - "confirm 60° at 30 hours in dry state
5	results in undetectable levels of virus." Did you
6	know that at that very same time studies had been
7	concluded in the United States in which Armour product
8	had been assayed by Dr Prince and, separately, by Dr
9	McDougal demonstrating quite to the contrary?
10	MR FUSON: I will object to the form of the question. It
11	assumes untrue facts.
12	MR SHRAGER: My question will need to be struck out, I
13	suppose, if I cannot prove what the results were of
14	that assay by Dr McDougal. Let me ask you the question
15	more broadly. Did you have any knowledge at that time
16	of subsequent work that, that is subsequent to your
17	quoted reference of August 1985 by Dr McDougal?
18	A. No. I can't recall it.
19	Q. Did you know at the time of this July 1986 memo that
20	Armour was months into work, laboratory work, at Meloy
21	to prepare for a licence submission in October, for
22	licence amendment to the FDA?
23	A. Because the Meloy data is quoted here, I would think
24	that the data would form part of that submission.
25	Q. Did you actually see the Meloy data or, rather, did
26	someone give you certain information with respect to
27	it. I ask you in the context that there is a specific
28	reference to Meloy data showing that "inactivates >5.5

1	logs"?
2	A. I cannot recall seeing the actual document but it makes
3	reference here to "Internal memo 3.12." but I cannot
4	testify that I actually saw that memo.
.5	Q. Do you recall if you can fairly remember that while
6	that much may be true so far $a\overline{s}$ it goes, that the Meloy
7	data showed residual virus?
8	A. I cannot recall.
9	Q. I see. Okay.
10	MR FUSON: Let me retrospectively lodge my objection to it.
11	It is true as far as it goes, part of the question, as
12	to the form.
13	MR SHRAGER: I think that was very apt. We might even find
14	that.
15	MR FUSON: It was apt as to argument. I think it was
16	improper as to a question.
17	MR SHRAGER: Now, Sir, had you received by that time any
18	report on the Prince data. "By that time" referring,
19	of course, to July of 1986?
- 20	A. I don't recall that.
. 21	Q. I think it developed in earlier questions that you knew
22	of Dr Prince. You were good enough to volunteer as to
23	who he was, as I remember your answer. Did anyone ever
24	share with you at any point in time in summary form or
25	otherwise what his data indicated?
26	A. I don't recall any thing like that.
27	Q. Now can you explain after these several questions why
28	it is that in this "defence" statement, you chose not
1	

to refer to the Whitmore cases? 1 Which date were you referring to? This memo, 2 Α. 19th June, or ---? 3 No, Sir, not, because in this memo of June as we have Q. 4 established Case 3 is a Whitmore patient. I am asking 5 you rather to go back, please, to the very document you 6 have in front of you and tell me why at no point in 7 time - I am now broadening the question - right up to 8 and through the time of the licence revocation in the 9 U.K. do you ever refer to the Whitmore cases? 10 MR FUSON: I object to the form of that. If you want to 11 show him documents in which he has made statements like 12 this or you want to ask him about the documents I think 13 that is fine. 14 MR SHRAGER: If I am conceivably wrong in my estimate of the 15 facts there, I will limit it to the July document. 16 MR FUSON: I object --17 MR SHRAGER: Why did you not ---18 MR FUSON: I object to your question. 19 MR SHRAGER: Isn't it a fact, Sir, that the only reason you 20 did not make reference to Dr Whitmore's cases - cases 21 which we have seen from other documents you knew about 22 23 - is that as a marketing matter you did not think it 24 prudent to share information that had not yet appeared 25 in the medical literature? The reason it did not appear in that is, I repeat my 26 Ά. earlier statements, referring to Mr Christie's memo 27 28 again, or these two memos in there now, which refer to

the confidential nature of that information. And again, referring to my previous statement where I said that unless material is cleared by the clinical and technical affairs department it would not appear in a sales and marketing document.

- 6 Q. Would you look on that same page 3, under the title "Bradford, Birmingham, Leeds, Hammersmith..." - you see that?
- 9 A. Yes.

1

2

3

4

5

The content that follows says: "No reports from the Q. 10 above, almost exclusively on Armour, or other U.K. 11 Centres of sero-negative conversions since 12 U.K. introduction of H.T. product in November/December 13 1984." Is that statement factually correct, Sir? 14 They report... That relates to information or reports 15 Α. from those centres, or lack of reports from those 16 centres, upon which we would be authorised to comment. 17 In that context, what about again Dr Whitmore's Q, 18 patients? 19

20 A. Well, we weren't authorised to make reference to Dr
21 Whitmore's patient.

22 Q. And who withheld authorisation?

A. Precisely who, I do not know, but it would have
been... We would not have had permission from that
department to include that report in the sales and
marketing document. The point I was trying to make
here is that with that percentage of the market and the
amount of material supplied is - especially these

	larger centres - there were no reports of sero-
	conversion, which had been checked out and cleared by
5	
Ĺ	Q. Precisely the point of my last question. Here in this
Ę	
e	
. 7	
8	
9	
10	
11	MR FUSON: I object to the form of that question. It was a
12	
13	
14	authorisation"?
15	A. Clinical and medical - technical affairs department of
16	
17	Q. Is it your best recollection now that we have reviewed
18	this that you took up with them the subject of Dr
19	Whitmore's patients and they told you not to refer to
20	them?
21	A. I can't recall specifically taking up the case of Dr
22	Whitmore.
23	Q. If you did not take it up with them, there would be no
24	occasion for them to withhold authorisation, correct?
25	A. Correct. If I had not taken it up with them.
26	Q. Definitionally there would be no occasion. Is it your
27	best recollection that that department did withhold
28	authorisation?

ì

161

 1. 20

1	MR FUSON: I object to the form of the question which
2	included a comment on a previous answer.
	MR SHRAGER: Is it your best recollection that the Revlon
4	people at Eastbourne withheld authorisation?
5	A. Yes, because thinking back I do recall a specific
6	request from Dr Whitmore that this information should
7	be deemed highly confidential. If you refer back to
. 8	previous facts, or the report from Bob Christie to Dr
. 9	Harris you will see in there that it is underlined,
10	about the reference of confidentiality of Dr Whitmore's
11	patient.
12	Q. So that the bench mark for whether or not you were to
13	report was whether you had permission from the
14	clinician?
15	A. The bench mark for the medical and technical affairs
16	department, whether to act upon that, would have been
17	from the clinician. My bench mark would have been the
18	permission from the clinical and technical, medical
19	affairs department.
20	Q. Revlon - right?
21,	A. Yes.
22	Q. And may I properly assume that if you had received
23	permission from Revlon but for some reason had been
24	requested by the clinician not to refer to the case,
25	you would have understood how to refer to it without
26	disclosure of the clinician or, of course, the patient.
27	MR FUSON: Objection, no foundation that the witness had
28	contact with the clinician concerning the patient.

1	recommended to Armour and Revlon people in the States,
2	that they prepared a defence document?
3	A. I can't recall a specific request in writing, unless
4	the July
5	Q. My question only calls upon your recollection. Do you
6	remember being part of any discussion with the
7	Americans concerning the need for a defence document?
8	A. I really can't recall the actual discussions.
9	Q. Let me try to put this in context, if I can.
10	MR FUSON: I will object already.
11	MR SHRAGER: Forget the first part. New question: as of
12	July 1986 as the director of marketing were you
13	seriously concerned about the adverse impact on your
14	sales of haemophiliac by discussion in the literature
15	of alleged seroconversions in association with the
16	product?
17	A. I was concerned at the interpretation being placed by
18	competition especially on those reports.
19	Q. And apropos of that, item 4 under "Objective" says that
20	you wanted to stop " any further deterioration in
21	sales - U.K. <u>+ Scandinavia</u> ." Were sales deteriorating
22	in those territories?
23	A. They must have been at that time. I can't recall
24	exactly now, exactly to what extent.
25	Q. And on the last line of that page, still the July 16
26	document, you say: "I would emphasise that this
27	document is essentially for the maintenance of
28	FACTORATE business in our markets." Did you believe

÷

	ļ.	
1	-	that to be true?
2	А.	Yes.
3	Q.	And this is the one that is copied to the President of
4		Armour?
- 5	A.	Yes.
6	Q.	And would you read the language that appears. First,
7		is that in your handwriting?
8	А.	Yes.
9	Q.	Would you read it, please?
10	A	"The declaration by M. Rodell in the Guardian"
11	Q.	You didn't start at the beginning. Start at the
12		beginning?
13	Α.	That is "PH" - that is Paul Harris Peter Harris.
14	Q .	Peter Harris.
15	А.	"17th July" - that is the day after this memo.
16	Q.	Yes. Read the words slowly please?
17	Α.	This is my comment to him.
18	Q.	This is a reference you are making on a copy of the
19		document that goes to him?
20	А.	No. This is a note I would have made on my file copy
21		of a subsequent telephone conversation, or verbal
22	Q.	Right.
23	А.	statement to him.
24	Q.	After he had received the document?
25	Α.	Yes.
:26	Q	Okay. Now read the content?
27	Α.	"The declaration by M. Rodell in the Guardian that our
28		H/T procedure is under review now negates a defence
		176

document for the 60°. 30 hrs." 1 MR SHRAGER: Ah. 2 MR FUSON: Was the "Ah-ha" part of your next question? 3 I did not even know it was MR SHRAGER: No, it wasn't. 4 going to be heard. 5 MR FUSON: Or an editorial comment on the answer? 6 You do not have a jury to react to it here. 7 MR SHRAGER: Did this reference by Dr Harris comes as quite 8 a shock to you? 9 MR FUSON: Excuse me, did the witness testify this was 10 something he told Dr Harris? 11 I thought... I had the impression that Dr MR SHRAGER: 12 Harris told you this? 13 No. That is my comment to him. Α. 14 I beg your pardon. Q. How had you learned of it? By 15 reading the Guardian over coffee in the morning? 16 I cannot remember. 17 A. I honestly cannot remember the article either. 18 Was it, if you can recall, that very morning, that is 19 Q. to say the Guardian of July 17, 1986? 20 I don't know it was the Guardian of the 17th July. 21 ||A. Did you know current to that time that the 60°/30 hour 22 Q. process was under review? 23 24 A. I don't recall. May it be that the first you heard about it was in the 25 2. newspaper? 26 MR FUSON: Are you asking him to speculate about that in the 27 form of your question? 28

1	MR SHRAGER: I am entitled to ask such a question in a
2	deposition?
3	A. I can't recall, but it would not have been. It would
4	not have been the first recollection, I am sure.
5	Q. Is it correct that up to that point in time, there had
6	been public reference to 60/30 being under review?
7	That is, outside the company.
8	MR FUSON: By "public" - is that?
9	MR SHRAGER: Public reference. Outside the company, that
10	you had not said to any clinician that 60/30 was under
11	review, you had not said to any press people or anyone
12	else 60/30 was under review?
13	MR FUSON: What are you referring to?
14	MR SHRAGER: I am referring to the meeting with the British
15	Government tat occurred on March 5, 1986 in which Dr
16	Rodell told the government members that some changes
17	to our heating cycle were also planned in the shorter
18	term, before Monoclate was available.
19	Q. I have no problem with that, if you would call my
20	attention to the documents. It is a little unusual to
21	do it mid-stream of the question, so now let me broaden
22	the question.
23	MR FUSON: Lots of unusual things happen here. Some of them
24	are in your questions and some of them are at my
25	responses.
26	MR SHRAGER: I take that kindly, and it goes both ways. So
27	up to July 16 to the best of your knowledge there had
28	not been any public disclosure of the 60/30 recipe
	178
	L/O
,	

being under review. Is that correct? By "public 1 disclosure" I mean that was available, known to, 2 the media or to the clinicians? 3 I object to this. You are now asking him to MR FUSON: 4 characterise whether the British Department of Health 5 and Human Services was in a position to discuss what Dr 6 Rodell had said? 7 MR SHRAGER: Of course they were in a position to discuss. 8 My question did not have to do with DHSS. 9 MR FUSON: You are asking whether it was available and, in 10 that sense, assuming it was a public body 11 MR SHRAGER: Good. Question withdrawn. Was there any 12 disclosure to the public at large in the media or to 13 clinicians about 60/30 being under review prior to July 14 16, 1986? 15 Not that I am aware of. 16 A. And is it correct that the Guardian, the statement by 17 Q. Dr Rodell to the Guardian, essentially pulled the plug 18 on your attempt to repair the marketing situation? 19 20 MR FUSON: Object to the form of the question. 21 MR SHRAGER: Your answer please? 22 A. Pulled the plug? 23 MR FUSON: I am not sure that "pulled the plug" is a British idiom in this context. 24 25 MR SHRAGER: Well, do you get the point - pulled the plug on you? 26 27 A. Yes, but the connotation may be different. 28 MR SHRAGER: You characterise it.

1 MR FUSON: Why don't you ask a different question that doesn't involve the slang expression? 2 There appears, if you would go a few pages MR SHRAGER: 3 further - this is now past the July 16 document - you 4 see there is a handwritten page. It says 5 "Proposed...". I can't read all the words. "... 6 Defence Document....". Is that in fact all in your 7 handwriting - the first page, please? 8 Yes. A. 9 Just to identify in the record. Q. 10 MR FUSON: Why don't you just look at that compared to the 11 document you are just asking him about? 12 That is fine. SHRAGER: MR I am going to do that 13 momentarily, but I cannot tell if all the handwriting 14 is the same. Is all the content of that page in your 15 hand? That is my first question ? 16 Yes. Α. 17 All right. Is that the document which, so far as you 18 Q. can tell, is verbatim typed out on July 16, the so-- 19 called "Proposed U.K. Defence Document"? 20 MR FUSON: Do you want him to read it word for word against 21 each other? 22 MR SHRAGER: That is why I said essentially, I said "so far 23 as you can tell." 24 25 MR FUSON: You said "verbatim" which does not mean.... MR SHRAGER: Do you have a recollection that you wrote this 26 out, turned it over to a secretary; she perhaps drafted 27 it up for you and then in some final form it became the 28

	1	А.	"CRB to ask P. Jones."
	2	Q.	About the subject matter that prec
	3	Α.	That is Dr Peter Jones.
	4	Q.	Dr Peter Jones a?
	5	А.	Is a clinician.
•	6	Q.	What specialty?
	7	Α.	Haematologist. He is centre dire
	8	Q.	At which centre?
	9	А.	Newcastle.
1	ò	Q.	Is he a colleague with whom
1	1		professional relationship?
1	2	А.	Not a colleague. He is a custom ϵ
1	3	Q.	A customer, with whom you have
1	4		relationship?
1	5	Α.	Yes.
1	6	Q.	When last did you speak to Dr Jones?
1	7	А.	Three weeks ago.
1	8	Q.	Have you ever discussed any litigation pending in the
1	19		United Kingdom involving Armour with Dr Jones?
2	20	А.	No.
2	21	Q.	Next there is the USA "Levine" letter. To what letter
ć	22	-	are you referring?
2	23	А.	This is the proposed letter which was discussed in
ć	24		Milan, which was called the NHF Sero-Conversion Review.
2	25	Q.	Have you seen the Levine letter?
Å	26	А.	I did see it. I recall seeing it in Milan.
ź	27	Q.	Have you seen it?
	28	Α.	But there was no copy. It was a draft letter which I
		1	·

recall at that time. 1 Submitted to you by Dr Levine in draft form? Q. 2 I saw a draft. A draft was shown to me but I No. 3 Α. can't remember by who, in Milan. 4 But whatever was shown to you, did it appear to be a Q. 5 draft letter by Dr Levine? 6 Yes, on behalf of the Medical Review Board of the ---Ά. 7 8 Haemophilia. Q. Met the Review Board of who? 9 Of the U.S. Haemophilia Society. Here you are - the Α. 10 NHF Medical Council. 11 You are referring now to a June 19, 12 Q. 1986 dated document, the Bishop to Lucas memo and this was a draft 13 letter, this reminds you, of Dr Levine to the NHF 14 Medical Council? 15 MR FUSON: I think he said on behalf of. 16 MR SHRAGER: Or on behalf of? 17 Yes. Α. 18 Q. Addressed to who? 19 I can't recall exactly. Α. 20 Well, what was Dr Levine's status, if you know, for the 21 Q. NHF Medical Council? 22 What was its status? ||A. 23 Yes? Q. 24 Α. As far as I can recall, a member of the Board. 25 Q. Okay. He had a draft letter addressed to who, please? 26 27 A. I can't recall all the addressees. 28 Q. Who was among them?

	11		
	1 A.	The chapters of the NHF.	
	2 2.	And did Worldwide?	<i>(</i> .
	3 A.	No, U.S.	
4	4 Q.	And this draft was shown to you in Milan?	
	5 A.	Yes.	
	5 Q.	Was it shown to you either by Dr Hilgartner or Dr	
7	7	Aledort?	• .
ε	3 A.	I can't recall exactly who showed it to me.	
ç	, Q.	Could it have been other than one of those two?	
10	A.	It could have been.	÷.
11	Q.	What was the general subject matter, please, of the	
.12		letter?	
13	A.	Since I headed here "Ser-Conversion Review".	
14	۵.	Understanding that, what was the substance of it? The	
15		topic was sero-conversion review. What kind of content	
16		did it have? What data did it purport to display?	
. 17	Α.	As far as I can recall it was a review of the data, the	
18		CO conversion data at that time.	•
19	Q.	Worldwide?	
20	Α.	Yes.	
21	Q.	Did you see Dr Levine in Milan?	
22\$	Α.	I can't recall seeing him specifically.	• .
23	Q.	Did you speak with him thereafter and prior to October	
24	· ·	of 1986? That is to say, within the next several	
25		months did you speak with Dr Levine?	
. 26	A.	I can't recall specific times.	
27	Q.	Did you ever see this letter in final form?	
28	Α.	I can't recall, no.	
		240	
			i z

-

-

	1	
	1 Q.	Did you receive a draft, or a copy of the draft letter?
:	2 A.	No. I was shown a copy.
-	3 Q.	You never retained a copy?
4	1 A.	No.
1 -	5 Q.	Would you read the words that follow the words "U.S.
e e	5	'Levine' letter." The 'Levine' is in quotes. That
۴	7	is, the words to the right of it. Read those please?
٤	3 A.	"Meeting RBC/LL" -
ç	, Q.	Standing for?
10	A.	Lofty Lucas. "/L. Aledort/S. Johnson."
11	Q.	And that reference to a meeting is at what local, if
12		you can tell me?
13	Α.	From what I can recall, it was Milan.
14	Q.	Okay. Does this refresh your recollection that there
15		discussions in Milan beyond the discussions to which
16		you earlier referred with Drs?
17	A.,	Sorry, can you repeat?
18	Q.	Yes. Does this mean that there were discussions in
19		Milan in addition to, or separate and apart from, your
20		earlier reference to the meeting with Drs. Aledort and
21		Hilgartner on the subject matter, on the broad subject
22,		matter, of reported sero-conversions?
23	Α.	Since Robert Christie appears with this group of
24		people, my recollection would be that this was a
25		separate meeting.
-26	Q.	And what was the principal subject matter of the
27		meeting, the Levine letter?
28	Α.	May I just read this.
		241
		241

1	Q.	Please go right ahead?
2	А.	To see what the meeting was about.
3	Q.	In fact, why don't you read it right onto the record?
4	А.	"Discussion on proposed letter to U.S. doctors - Levine
5		has no authority to ask for such a letter to be sent
6		until discussed with NFH Executive" - National
7		Federation of Haemophilia Executive - "including L.
8	3	Aledort, Hilgartner, etc."
ç	, Q.	Please continue?
10	А.	"Recommendation to " - it looks like "Dovey" but I
1	1	don't recall the name. "Recommendation to Dovey etc.
12	2	to delay and ask for meeting of scientists to discuss
1	3	all cases but Whitmore case confidential and details
1	4	cannot be disclosed without Whitmore's permission. If
1	5	letter goes so does <u>all</u> business world-wide."
1	6 Q	. "All" is underscored three times - right?
1	7 A	
1	80	
1	9 A	And then it has got. one it
	20	J" - that is Spencer Johnson - "recommends a rep.'s
	21	training course"
	22	2. What kind please?
	23 1	A. Rep's.
	24	2. Representatives?

"... training course to discuss information Yes. 25 A. arising from the expert's judgment of the 3 cases, 26 Chapel Hill, Amsterdam, Lewisham." 27 What about the first Whitmore case? There were two Dr 28 Q.

Whitmore cases, you recall?

1

:

		2 A. Um.
		3° Q. The first being one of a haemophiliac that had not
	4	received product for 5 years, or so it was reported in
	-	
	e	
	7	
	8	and had the my millio.
	9	Q. But at that time would you have known certainly of both
	10	Cases?
	11	A. Without refreshing my note, no.
	12	Q. You don't know. That is a fair answer if you don't
	13	remember or don't know. But if you do know, I would
•	14	like your best recollection?
	15	A. I can't remember.
	16	Q. What was
	17	MR FUSON: David, it is 7h10 and you said you only had a
	18	little bit more an hour again.
	19	MR SHRAGER: I don't want to bring them back.
	20	MR FUSON: I understand that but I don't want the witness to
	21	go on to the point where he is too tired to respond
	22,	properly.
	23	MR SHRAGER: I don't want him either. I assure you it is
	24	solely a function of the witness's comfort whether it
	25	is better to finish this afternoon, or come in in the
	26	morning and finish. I feel terrible because it could
	27	be merely another 10 minutes, but it could be half an
	28	hour. That is what I leave it to you. How do you

1	feel about it? Don't just agree to go forward to get
2	it over with.
3	THE WITNESS: No. I think we'll start I am staying here
4	anyway.
5	MR SHRAGER: Then let's continue. Do you mind continuing as
6	early as 9.00 a.m. Would that be okay? Okay.
7	(Adjourned until 9.00 a.m. on Friday 7th June)
8	
9	
10	
11	
12	
13	
14	
15 16	
17	
18	
19	
20	
21	
22,	
23	
24	
25	
26	
27	
28	
	244

-

•

. .